Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Capmatinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Capmatinib. Displaying page 1 of 1.
    EudraCT Number: 2020-003677-21 Sponsor Protocol Number: CINC280L12301 Start Date*: 2021-09-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum - pemetrexed based doublet chemotherapy in patients with loca...
    Medical condition: EGFR mutated, T790M negative NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) SI (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003097-11 Sponsor Protocol Number: CINC280J12201 Start Date*: 2020-07-20
    Sponsor Name:Novartis Pharma AG
    Full Title: A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo...
    Medical condition: non-small cell lung cancer with MET exon 14 skipping mutations
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10025048 Lung cancer non-small cell recurrent LLT
    20.0 100000004864 10025054 Lung cancer non-small cell stage IIIB LLT
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001578-31 Sponsor Protocol Number: CINC280A2301 Start Date*: 2020-08-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advance...
    Medical condition: cMET mutated NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) PT (Completed) FR (Completed) LT (Completed) BE (Completed) IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005144-42 Sponsor Protocol Number: CINC280A2X02B Start Date*: 2017-05-31
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, global, rollover study for patients who have previously received capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial
    Medical condition: cMET-dependent malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Completed) DK (Completed) FR (Completed) AT (Completed) SE (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001401-67 Sponsor Protocol Number: APHP201152 Start Date*: 2021-07-21
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Full Title: Phase II trial to evaluate the combination of capmatinib + spartalizumab in advanced oesogastric adenocarcinoma
    Medical condition: Patients with advanced oesogastric adenocarcinoma that have received at least one previous chemotherapy line with platinium salt and fluoropyrimidin and with a documented progression.
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084873 Gastrooesophageal junction cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002660-27 Sponsor Protocol Number: CINC280I12201 Start Date*: 2019-12-12
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally adva...
    Medical condition: non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) ES (Completed) GR (Completed) DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001420-19 Sponsor Protocol Number: CINC280D2201 Start Date*: 2019-01-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adul...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) BE (Completed) FR (Completed) GR (Completed) BG (Completed) NL (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-002288-69 Sponsor Protocol Number: CINC280A2203 Start Date*: 2020-09-03
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase II, Open-Label, Multicenter Study of Capmatinib in Participants with MET exon 14 skipping mutation positive, advanced, Non Small-Cell Lung Cancer that has metastasized to the Brain
    Medical condition: cMET mutated NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-000485-18 Sponsor Protocol Number: 61186372PANSC2001 Start Date*: 2023-05-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
    Medical condition: Unresectable Metastatic Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000610-38 Sponsor Protocol Number: CPDR001J2201 Start Date*: 2018-10-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
    Medical condition: Unresectable or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000726-37 Sponsor Protocol Number: CINC280X2105C Start Date*: 2014-11-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer
    Medical condition: non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005417-76 Sponsor Protocol Number: CINC280X2108 Start Date*: 2016-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003850-15 Sponsor Protocol Number: CINC280A2201 Start Date*: 2015-05-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC)
    Medical condition: Advanced non-small cell ling cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Ongoing) NL (Completed) FR (Completed) BE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001241-84 Sponsor Protocol Number: CINC280B2201 Start Date*: 2015-08-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Completed) NL (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002569-39 Sponsor Protocol Number: CINC280X2202 Start Date*: 2013-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have pro...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) ES (Completed) DE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002851-27 Sponsor Protocol Number: C16-40 Start Date*: 2018-10-08
    Sponsor Name:INSERM
    Full Title: MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS - A phase III study
    Medical condition: Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004414-35 Sponsor Protocol Number: IMPRESSNorway Start Date*: 2021-02-19
    Sponsor Name:Oslo University Hospital
    Full Title: Improving public cancer care by implementing precision medicine in Norway
    Medical condition: Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000203-20 Sponsor Protocol Number: MCLA-129-CL01 Start Date*: 2021-08-12
    Sponsor Name:Merus N.V.
    Full Title: Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
    Medical condition: advanced NSCLC and other solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000133-40 Sponsor Protocol Number: 2016-2369 Start Date*: 2016-05-25
    Sponsor Name:Gustave Roussy
    Full Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
    Medical condition: Relapsed or refractory tumors in children
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 11:50:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA